InvestorsHub Logo
Followers 30
Posts 1939
Boards Moderated 0
Alias Born 01/11/2011

Re: dukesking post# 219851

Thursday, 10/17/2019 11:15:45 AM

Thursday, October 17, 2019 11:15:45 AM

Post# of 425648
SA is hanging their hat on the sentence in Amarin PR that states:


"A separate independent, academic cost-effectiveness analysis of Vascepa based on patient-specific data from the REDUCE-IT study will be presented at the American Heart Association Scientific Sessions 2019 on November 16 by William S. Weintraub, M.D., Director of Outcomes Research, MedStar Cardiovascular Research Network. Amarin provided an unrestricted grant for this academically driven analysis, titled “Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT.”

But that is NOT referring to the ICER report.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News